Napredna pretraga

Pregled bibliografske jedinice broj: 376494

Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan?


Suzana Berend, Ana Lucić Vrdoljak, Božica Radić, Jasenka Piljac-Žegarac, Marin Mladinić, Davor Želježić, Nevenka Kopjar
Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan? // Toxicolgy Letters, Abstracts of the 45th Congress of the European Societies of Toxicology / Tsatsakis, Aristidis M., Liesivuori, Jyrki (ur.).
Rodos, Grčka, 2008. (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Is an antioxidative capacity of HI-6 oxime a key factor to improve the therapy with irinotecan?

Autori
Suzana Berend, Ana Lucić Vrdoljak, Božica Radić, Jasenka Piljac-Žegarac, Marin Mladinić, Davor Želježić, Nevenka Kopjar

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Toxicolgy Letters, Abstracts of the 45th Congress of the European Societies of Toxicology / Tsatsakis, Aristidis M., Liesivuori, Jyrki - , 2008

Skup
45th Congress of the European Societies of Toxicology

Mjesto i datum
Rodos, Grčka, 05-08.10.2008

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
HI-6; irinotecan; antioxidative capacity

Sažetak
New and improved therapy modalities currently employed in the management of malignant diseases significantly contribute to the overall survival rate in cancer patients. Therefore, some compounds although not primarily designed as supportive drugs in chemotherapy, are promising candidates for possible clinical use. Our in vitro and in vivo experiments have demonstrated that HI-6 could “ protect” cholinesterases against the irinotecan, one of frequently used antineoplastic drugs, and in that way a part of cholinergic symptoms might be reduced. Interestingly, certain antioxidants may counteract the effects of chemotherapy-induced oxidative stress on the cell cycle and enhance the cytotoxicity of antineoplastic agents. So with the purpose to investigate the levels of oxidative stress and DNA damage (lipid peroxidation, the alkaline comet assay and micronucleus assay) related to treatments with irinotecan and HI-6 given alone or in combination we also focused on the assessment of possible antioxidative capacity of HI-6. In view of the DPPH assay results, HI-6 shows moderate radical scavenging at the tested concentration. Administration of HI-6 alone or with irinotecan diminished the levels of TBARS in rat plasma. Confirmatory results regarding HI-6 efficacy were also obtained by the alkaline comet and micronucleus assay. When given alone, it mostly did not induce significant disturbances in the level of primary DNA damage in somatic cells of treated rats and did not significantly induce the formation of micronuclei. Results obtained in the present study seems to be a proper argument to consider HI-6 as beneficial substance during chemotherapy.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
022-0222148-2137 - Genotoksičnost kemijskih i fizikalnih agensa prirodnog i antropogenog podrijetla (Vilena Kašuba, )
022-0222148-2139 - Terapijski učinak novosintetiziranih spojeva pri otrovanju organofosfatima (Ana Lucić Vrdoljak, )
098-0982913-2829 - Molekularna regulacija biljnog razvitka (Branka Salopek-Sondi, )

Ustanove
Institut za medicinska istraživanja i medicinu rada, Zagreb,
Institut "Ruđer Bošković", Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE